Truist initiated coverage of Climb Bio (CLYM) with a Buy rating and $17 price target Climb is advancing two clinical-stage assets with “validated mechanisms and blockbuster potential” in Budoprutug and CLYM116, says the analyst, who sees “substantial potential upside” as clinical catalysts progress.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: